|
Fig. 5 Synergistic activity of AURKBi and Dasatinib in vitro and ex vivo. A-H) Synergy scores of drug combinations after 48 h of treatment with 0.005, 0.05, 0.5, 5 and 50 µM of Barasertib and Dasatinib in HD-MB03 (A), D425 (C), ONS-76 (E) and in D283 (G) cells. Synergy score of drug combination of GSK-1070916 and Dasatinib in HD-MB03 (B), D425 (D), ONS-76 (F) and in D283 (H) cells. I) Confocal microscopy IFA of OCSC-embedded D425 cells treated for 5 days with 100 nM Barasertib, GSK-1070916, or Dasatinib, and combinations of Barasertib and Dasatinib or GSK-1070916 and Dasatinib. Green: Anti-human nucleoli antibody, red: Click-iT® EdU, blue: anti-Cabindin, yellow: anti-GFAP. Human nuclei are displayed in inverted grey scale and EdU incorporation as volume renderings from Z-stack images. J) Heat map of TV and rPV of ONS-76, HD-MB03, D425 and D283 OCSC co-cultures after 5-days of treatments (n≥3 biological replicas, *p 0.0338).